Biomarker Discovery & Validation
News on biomarker discovery and validation for research and diagnostic use in genetics, genomics, and molecular diagnostics.
Esya Labs, Alamar Biosciences Partner on Biomarker Discovery Services
The companies will combine technologies to provide tailored assays for pharma firms developing therapies for neurological and inflammatory diseases.
Mursla Bio, a Cambridge, UK-based company that focuses on EV isolation, biomarker discovery from EV cargo, and EV assays for clinical use, is an EVEREST participant.
Element Biosciences, Qiagen Targeted NGS Helps ID Urine-Based cfDNA Biomarkers in Breast Cancer
Premium
At the AMP annual meeting, a University Hospital Leipzig researcher described using the NGS workflow to find promising urine-based biomarkers in triple-negative breast cancer.
23andMe, Mirador Therapeutics Ink Immunology Target Validation Deal
Mirador Therapeutics will leverage a targeted set of 23andMe's genetic data for immune-related biomarker and drug discovery.
Alamar Biosciences, Michael J. Fox Foundation Partner on Parkinson's Research
The partners will use Alamar's NULISA proteomics platform to develop assays for identifying biomarkers linked to neuronal synuclein diseases including Parkinson's.